NCT01505608 2024-08-06Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed NeuroblastomaMilton S. Hershey Medical CenterPhase 1/2 Terminated14 enrolled 11 charts
NCT01582152 2019-06-05Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent GlioblastomaM.D. Anderson Cancer CenterPhase 1/2 Terminated12 enrolled 7 charts